Cargando…

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis

Over the last years CFTR (cystic fibrosis transmembrane conductance regulator) modulators have shown the ability to improve relevant clinical outcomes in patients with cystic fibrosis (CF). This review aims at a systematic research of the current evidence on efficacy and tolerability of CFTR modulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gramegna, Andrea, Contarini, Martina, Aliberti, Stefano, Casciaro, Rosaria, Blasi, Francesco, Castellani, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461566/ https://www.ncbi.nlm.nih.gov/pubmed/32824306 http://dx.doi.org/10.3390/ijms21165882

Ejemplares similares

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2023)

Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience
por: Amati, Francesco, et al.
Publicado: (2022)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Not All Is CFTR – Neutrophils and Cholesterol in Cystic Fibrosis
por: Castellani, Stefano, et al.
Publicado: (2017)

Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
por: Pigliasco, Federica, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
por: Tsai, Alice, et al.
Publicado: (2020)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

When and how ruling out cystic fibrosis in adult patients with bronchiectasis
por: Gramegna, Andrea, et al.
Publicado: (2018)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis
por: Pedrazzi, Marco, et al.
Publicado: (2021)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over
por: Alicandro, Gianfranco, et al.
Publicado: (2022)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

The biology of pulmonary exacerbations in bronchiectasis
por: Amati, Francesco, et al.
Publicado: (2019)

Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash
por: Santos, Ana Isabel, et al.
Publicado: (2023)

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015)

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
por: Granger, Emily, et al.
Publicado: (2022)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
por: Sommerburg, Olaf, et al.
Publicado: (2021)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
por: Duckers, Jamie, et al.
Publicado: (2021)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
por: Kapouni, Nikoletta, et al.
Publicado: (2023)

SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy
por: Alicandro, Gianfranco, et al.
Publicado: (2022)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Cross‐talk between CFTR and sphingolipids in cystic fibrosis
por: Dobi, Dorina, et al.
Publicado: (2023)

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis
por: Haq, Iram, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_otndcovggsm4b7hibem2tufd7f